News
23 November 2023
Merger by incorporation of FRANCO MARTEGANI S.R.L. into DRAGOTTI & ASSOCIATI S.R.L.
We are pleased to announce that the merger by incorporation of FRANCO MARTEGANI S.R.L. ("FMA") into DRAGOTTI & ASSOCIATI S.R.L. ("DEA") will be effective from December 1st, 2023...
News
03 October 2022
Roberto Pistolesi is the new President of FICPI
Roberto Pistolesi, partner and CEO of Dragotti & Associati, has been elected President of the International Federation of Intellectual Property Consultants.
News
14 July 2022
Dragotti & Associati acquires Franco Martegani S.r.l., expanding in the Monza-Brianza area
Dragotti & Associati has perfected the acquisition of Franco Martegani, a renowned intellectual property consultancy firm based in Monza.
News
11 February 2021
Latest Brexit Updates
Dear Sirs, we would like to give you the main insights into what will happen to your European/Community rights when Brexit comes into effect.
News
18 March 2020
COVID-19: emergency contacts
Following recommendations from the Italian Government, we have decided to implement home office: to urgently contact us, we suggest to use this list of cellular phones.
News
01 July 2019
The Regulation (EU) No 2019/933, published in the Official Journal of the European Union on June 11, 2019, will enter into force on July 1st, 2019.
The Regulation (EU) No 2019/933, published in the Official Journal of the European Union on June 11, 2019, will enter into force on July 1st, 2019.The Regulation, which amends Regulation (EC) No 469/2009 concerning the supplementary protection certificate (SPC) for medicinal products, seeks to strike a balance between the rights of producers of generics and biosimilars established in the Union and those of producers based outside the Union.The Regulation (EC) No 469/2009 provides for extension of the term of a patent relating to protection of medicinal products subject to Marketing Authorization by five years (there is a further 6-month extension of patent protection for pediatric pharmaceuticals).The absence in Regulation (EC) No 469/2009 of any exception to the protection conferred by an SCP has had the unintended consequence of preventing producers of generics and biosimilars established in the Union from manufacturing generics and biosimilars in the Union, even for the purpose of export to third-country markets in which protection does not exist or has expired. Likewise, producers are prevented from manufacturing generics and biosimilars for the purpose of storing them for a limited period before expiry of an SPC.The aim of the new Regulation is to promote the competitiveness of the Union, preventing relocation of pharmaceutical research outside the Union, thereby enhancing growth and job creation in the internal market and contributing to a wider supply of products under uniform conditions, by allowing producers of generics and biosimilars established in the Union to compete, on the one hand, in rapidly developing global markets in which protection does not exist or has expired and, on the other, in the Union market upon expiry of the SPC.To that end the new art. 5 of Regulation (EU) No 2019/933 provides for an exception to the protection conferred by an SPC so as to allow the manufacturing of a product, or a medicinal product containing that active principle, for the purpose of export to third countries in which protection of the original product does not exist or has expired, or of storing (i.e. for supply immediately after expiry of the patent protection), and any related acts including: possessing; offering to supply; supplying; importing; using or synthesizing an active ingredient for the purpose of making a medicinal product; or temporary storing or advertising for the exclusive purpose of export to third-country destinations.
News
07 December 2018
MARCHI +3 Rifinanziamento del programma e riapertura bando
Il Ministero dello Sviluppo Economico, ha reso noto che è stato rifinanziato il programma di agevolazioni alle imprese per favorire la registrazione di marchi dell'Unione europea ed internazionali Marchi+3.
News
Roberto Pistolesi speaks about “Disclosures in the grey area” at FICPI’s 17th Open Forum in Venice on October, 26 2017
Disclosures that are alleged to be “prior art” may sometimes have uncertain status.
News
05 October 2015
Mr. Gianfranco Dragotti has been appointed co-chair of AIPPI's Standing Committee on PCT.
Mr. Gianfranco Dragotti, president and founder of Dragotti & Associati, has been appointed co-chair of AIPPI's Standing Committee on PCT.
News
08 July 2015
Italy adheres to the unitary patent
We inform you that the Italian Government officially confirmedItaly's adherence to the unitary patent.
News
05 June 2015
Dragotti & Associati wins another “quetiapine case” in Sandoz vs. AstraZeneca
the Specialized Section of the Turin Court confirmed that the Italian portion of AstraZeneca’s European patent EP907364B1 is invalid since it lacks inventive step.
News
22 April 2015
News
16 April 2015
RobertoPistolesi has been elected as Secretary General of FICPI.
Dragotti & Associati is proud and honored to announce that, during FICPI’s executive committee meeting held in Cape Town on last April 13, its partner and CEO, RobertoPistolesi, has been elected as Secretary General of FICPI.
News
13 April 2015
Dragotti & Associati wins quetiapine PI case in Accord vs. AstraZeneca
With an order issued on April 1, 2015, the Specialized Section of the Turin Court confirmed that no preliminary injunctions can be granted against Accord, since AstraZeneca’s European patent EP907364B1 would prima facie lack inventive step.
News
16 January 2018
Convegno sulla Consulenza Tecnica d’Ufficio (2° modulo)
Milano, 6 febbraio 2018 - (14:15 - 18:15)